Published in Hepatology on August 01, 1999
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One (2008) 1.14
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol (2014) 1.10
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol (2015) 1.10
HBV life cycle and novel drug targets. Hepatol Int (2011) 1.03
T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol (2012) 0.97
Present and future therapies of hepatitis B: From discovery to cure. Hepatology (2015) 0.96
Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol (2014) 0.88
Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol (2004) 0.85
Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. Hepatology (2010) 0.84
CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol (2001) 0.83
Virologic characteristics of hepatitis B virus in patients infected via maternal-fetal transmission. World J Gastroenterol (2008) 0.83
Advances in immunomodulating therapy of HBV infection. Int J Med Sci (2005) 0.83
Hepatitis B: future curative strategies. Curr Opin Infect Dis (2014) 0.81
Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol (2014) 0.81
Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol (2006) 0.80
Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol (2007) 0.80
Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load. J Med Primatol (2006) 0.80
Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol (2011) 0.79
Immune therapy of hepatitis B virus chronic infection. Hepatology (2000) 0.78
Immune therapy for hepatitis B. Ann Transl Med (2016) 0.77
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat (2010) 0.77
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck. Med Microbiol Immunol (2014) 0.76
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
How much help does a vaccine-induced T-cell response need? J Clin Invest (2001) 0.75
Immunostimulatory activities of dendritic cells loaded with adenovirus vector carrying HBcAg/HBsAg. Int J Clin Exp Med (2015) 0.75
An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells. PLoS One (2014) 0.75
HBV Core Protein Enhances Cytokine Production. Diseases (2015) 0.75
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Sex and gender bias in anatomy and physical diagnosis text illustrations. JAMA (1994) 7.51
Nosocomial klebsiella infections: intestinal colonization as a reservoir. Ann Intern Med (1971) 6.55
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Diversity and depth-specific distribution of SAR11 cluster rRNA genes from marine planktonic bacteria. Appl Environ Microbiol (1997) 4.71
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Case-finding for depression in primary care: a randomized trial. Am J Med (1999) 4.46
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Chemoattractant-mediated transient activation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyostelium. EMBO J (1999) 4.34
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry (2008) 4.14
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med (1997) 3.55
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Crystal structure of the yeast TFIIA/TBP/DNA complex. Science (1996) 3.45
Estimating the growth rate of slowly growing marine bacteria from RNA content. Appl Environ Microbiol (1993) 3.45
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology (2000) 3.42
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Switchable ferroelectric diode and photovoltaic effect in BiFeO3. Science (2009) 3.39
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
T-DNA insertional mutagenesis for functional genomics in rice. Plant J (2000) 3.25
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2003) 3.24
A Smad transcriptional corepressor. Cell (1999) 3.07
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis (2011) 2.97
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol (2000) 2.90
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study. Aliment Pharmacol Ther (2012) 2.80
The crystal structure of the peptide-binding fragment from the yeast Hsp40 protein Sis1. Structure (2000) 2.80
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Continuous negative extrathoracic pressure in neonatal respiratory failure. Pediatrics (1996) 2.75
Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol (1998) 2.74
Paediatric hand fractures. J Hand Surg Eur Vol (2013) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Immunological self, nonself discrimination. Science (1987) 2.59
A quasi-monoclonal mouse. Science (1996) 2.58
Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol (1993) 2.57
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis (1988) 2.56
Endothelial-leukocyte adhesion molecule 1 stimulates the adhesive activity of leukocyte integrin CR3 (CD11b/CD18, Mac-1, alpha m beta 2) on human neutrophils. J Exp Med (1991) 2.52
Knowledge and attitudes about depression among non-generalists and generalists. J Fam Pract (1997) 2.51
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Ohm's law survives to the atomic scale. Science (2012) 2.40
The mosaic organization of the apocytochrome b gene of Aspergillus nidulans revealed by DNA sequencing. Cell (1981) 2.38
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia (2008) 2.37
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis (2000) 2.35
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell (1992) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
The mouse pink-eyed dilution gene: association with human Prader-Willi and Angelman syndromes. Science (1992) 2.23
Reaching our successors: the trend for early specialisation and the potential effect on recruitment to our speciality. J Plast Reconstr Aesthet Surg (2008) 2.21
CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity (1997) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: the Korea NHANES study. Int J Obes (Lond) (2006) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
The tomato Never-ripe locus regulates ethylene-inducible gene expression and is linked to a homolog of the Arabidopsis ETR1 gene. Plant Physiol (1995) 2.11
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis (2000) 2.08
Pathogenesis of the slow disease of the central nervous system associated with WM 1504 E virus. I. Relationship of strain susceptibility and replication to disease. Am J Pathol (1977) 2.08
Influence of thymic genotype on the systemic lupus erythematosus-like disease and T cell proliferation of MRL/Mp-lpr/lpr mice. J Exp Med (1981) 2.07
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med (1999) 1.98
Pitfalls in current methods of CDH detection. J Paediatr Child Health (1991) 1.98
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng (2005) 1.97
Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med (2001) 1.96
Cytokinins and auxins control the expression of a gene in Nicotiana plumbaginifolia cells by feedback regulation. Plant Cell (1992) 1.95
Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc Psychiatry (1998) 1.94
EUS in cirrhotic patients with and without prior variceal hemorrhage in comparison with noncirrhotic control subjects. Gastrointest Endosc (2000) 1.94
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Immunologic competence of thoracic duct cells. I. Delayed hypersensitivity. J Exp Med (1966) 1.89